Vistusertib - AstraZeneca
Alternative Names: AZD 2014Latest Information Update: 26 Jul 2024
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Cambridge University Hospitals; Massachusetts General Hospital; National Cancer Institute (USA); Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; Queen Mary University of London; Samsung Medical Center; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
- Class 2 ring heterocyclic compounds; Antineoplastics; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Meningioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 12 Apr 2024 AstraZeneca completes a phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Japan (PO) (NCT02398747) (JapicCTI152863)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 23 Nov 2023 AstraZeneca completes a phase I/II trial in Breast cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in the US and united kingdom (NCT02599714)